Abstract
Background Oral dabigatran etexilate is indicated for the prevention of systemic thromboembolic events in patients with non-valvular atrial fibrillation (NVAF). Based on the RE-LY study we investigated the cost-effectiveness of dabigatran etexilate versus warfarin and versus others new oral anticoagulants (rivaroxaban and apixaban) in the Italian setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
